Elixiron Immunotherapeutics, a privately held company developing therapeutics for cancer, neurological diseases and inflammatory disorders, has announced the closing of a Series A-1 extension financing round, bringing the total Series A-1 raise to $27 million.

Elixiron was founded in 2017 and is led by Hung-Kai Chen, Founder, CEO and Chairman of the Board. The financing raise was jointly led by Pangu Capital (a new investor) and Taiwania Capital (an existing investor) and was joined by further new investors, including DCI Partners of Daiwa Securities Group, Mega International Commercial Bank, Fubon Financial Holdings and Hong Tai Electric Industrial, as well as other existing investors such as China Development Capital Industrial Bank (CDIB) Capital Group.